# OnCo record paper-telli-hrd-score-platinum-tnbc-ccr-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-telli-hrd-score-platinum-tnbc-ccr-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-telli-hrd-score-platinum-tnbc-ccr-2016" ;
  schema:name "Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer"@en ;
  schema:description "A genome-scar score built from three measures of chromosomal damage, with 42 as the cut-off, picked out triple-negative tumours that melted away on platinum chemotherapy before surgery, including tumours without a BRCA mutation."@en ;
  schema:url <https://onco.cc/key-papers/paper-telli-hrd-score-platinum-tnbc-ccr-2016/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/1078-0432.CCR-15-2477>, <https://pubmed.ncbi.nlm.nih.gov/26957554/> ;
  schema:sameAs <https://doi.org/10.1158/1078-0432.CCR-15-2477> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Telli ML, Timms KM, Reid J, et al." ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/hrd-testing/>, <https://onco.cc/technologies/hrd-genomic-scar-scores/>, <https://onco.cc/technologies/platinum/> ;
  onco:targets <https://onco.cc/targets/brca/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/mychoice-cdx/> ;
  onco:companies <https://onco.cc/companies/myriad-genetics/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/pcr/> ;
  onco:journals <https://onco.cc/journals/clinical-cancer-research/> .